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Abstract
Purpose:  To  evaluate  the  safety  and  efﬁciency  of  preoperative  portal  vein  embolization  (PVE)
with a  combination  of  trisacryl  microspheres,  gelfoam  and  coils  for  inducing  lobar  hypertrophy
in hepatobiliary  malignancy  patients.
Materials  and  methods:  PVE  was  performed  by  a  percutaneous  left  approach  in  63  patients
with hepatic  malignancy  (hepatocarcinoma  =  38,  colorectal  metastasis  =  14,  cholangiocarci-
noma =  11).  The  indication  of  PVE  and  surgery  was  evaluated  by  hepatic  tumor  board  take  into
consideration  to  the  tumor  extension  and  the  hepatic  volume  on  initial  and  post-embolization
CT-scans.  The  total  functional  liver  volume  (TELV)  and  future  liver  remnant  (FLR)  volume  were
measured  before  and  24  ±  5  days  after  PVE  to  assess  FLR,  TELV  and  FLR/TELV  ratios.  Efﬁciency
evaluation was  based  on  FLR  increase,  the  ability  to  perform  the  hepatectomy  and  the  hepatic
function after  surgery.  Safety  evaluation  was  determined  by  clinical  and  biological  follow-up
after embolization  and  surgery.
Results:  PVE  was  successful  in  all  the  patients.  The  mean  FLR  volume  increases  by  57  ±  56%  after
embolization  (449  ±  180  cm3 to  663  ±  254cm3)  (P  <  0.0001).  The  FLR/TELV  ratio  increases  by  11%
after PVE  (25  ±  8%  to  36  ±  12%).  Three  minors’  complications  were  registered  without  impact  on
surgery, and  four  patients  developed  portal  hypertension.  Forty-nine  patients  underwent  hepa-
tectomy; none  of  them  developed  liver  failure.  Surgery  was  not  performed  in  14  patients  due  to
tumor progression  (n  =  9),  inadequate  hypertrophy  of  FLR  (n  =  1)  and  portal  hypertension  (n  =  4).
Conclusion:  Preoperative  PVE  with  a  combination  of  trisacryl  microspheres,  gelfoam  and  coils
is a  safe  and  effective  method  fo
in patients  with  advanced  hepat
© 2013  Éditions  franc¸aises  de  rad
∗ Corresponding author.
E-mail address: julien.cazejust@sat.aphp.fr (J. Cazejust).
2211-5684/$ — see front matter © 2013 Éditions franc¸aises de radiologie
http://dx.doi.org/10.1016/j.diii.2013.07.004r  inducing  contralateral  hypertrophy  before  right  hepatectomy
obiliary  malignancy.
iologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
. Published by Elsevier Masson SAS. All rights reserved.
5m
m
(
n
v
i
i
[
s
a
n
e
r
t
m
u
e
s
l
r
r
n
M
P
A
i
r
J
r
t
i
t
a
m
a
r
e
o
t
a
t
I
s
i
l
a
t
o
b
d
a
b
u
r
t
(
g
p
w
1
o
i
2
P
E
o
f
i
a
t
a
u
t
C
t
t
(
c
v
p
t
i
s
r
a
o
s
l
ﬂ
w
c
n
(
I
r
v
t
e8  
Major  hepatectomy  (resection  of  four  or  more  liver  seg-
ents)  is  associated  with  increased  morbidity  and  mortality
ainly  due  to  liver  insufﬁciency.  Portal  vein  embolization
PVE)  is  intended  to  obtain  hypertrophy  of  future  liver  rem-
ant  to  minimize  the  risk  of  postoperative  liver  failure.
PVE  is  a  well-established  procedure,  but  it  is  extremely
ariable  from  one  center  to  another,  probably  because  there
s  no  consensus  in  the  literature  on  which  embolic  agent
nduces  the  greatest  degree  of  liver  hypertrophy  after  PVE
1].  Many  embolic  agents  have  been  used  in  the  literature,
uch  as  n-butyl  cyanoacrylate  (NCBA),  microparticles,  coils,
lcohol,  nitinol  plugs  [2].  At  the  beginning  of  the  study,
o  clinical  study  had  demonstrated  an  advantage  of  one
mbolic  agent  compared  to  the  others.  However,  a  very
ecent  retrospective  study  [3]  seems  to  demonstrate  that
he  use  NCBA  could  induce  a  better  hypertrophy  than  using
icroparticles  plus  coils.
Although  it  is  a  common  practice  in  many  institutions  to
se  a  combination  of  particulates  and  coils  to  perform  the
mbolization,  PVE  using  a  combination  of  trisacryl  micro-
pheres,  gelfoam  and  coils  has  never  been  described  in  the
iterature.
Our  objective  was  to  analyze  the  outcomes  of  PVE  before
ight  hepatectomy,  in  terms  of  liver  hypertrophy,  resection
ates,  and  complications  after  embolization  with  a  combi-
ation  of  trisacryl  microspheres,  gelfoam  and  coils.
aterial and methods
atients
 retrospective  monocentric  study  was  performed,  includ-
ng  all  patients  undergoing  PVE  for  liver  malignancy  who
equired  right  hepatectomy,  between  February  2009  and
anuary  2013.  Our  local  ethics  committee  approved  the
etrospective  analysis  of  the  data,  and  all  patients  gave
heir  written  informed  consent  for  the  procedure.  The
ndications  of  right  hepatectomy  or  extended  hepatec-
omy  and  presurgery  embolization  were  elaborated  through
 case-by-case  discussion  at  the  weekly  meeting  of  the
ultidisciplinary  hepatobiliary  tumor  board  (including  hep-
tologists,  oncologists,  liver  surgeons  and  interventional
adiologists).
Pre-embolization  CT  was  performed  to  determine  the
xtent  of  hepatobiliary  disease,  the  presence  or  absence
f  extra-hepatic  disease  and/or  distant  metastasis,  the  por-
al  vein  and  hepatic  artery  permeability,  the  presence  or
bsence  of  portal  vein  variants,  and  biliary  obstruction.
The  portal  vein  embolization  was  suggested  according  to
he  hepatic  volumetry  and  underlying  hepatic  disease  [1].
n  case  of  healthy  liver,  the  Future  Liver  Remnant  (FLR)
hould  be  at  least  25%  of  the  total  liver  volume;  whereas
n  case  of  liver  cirrhosis,  the  FLR  must  be  at  least  40%  of
iver  volume.  For  patients  undergoing  previous  chemother-
py,  the  FLR  should  be  at  least  30%  of  liver  volume  [1].  For
hree  patients,  although  the  volume  of  FLR  was  over  25%,
n  a  non-cirrhotic  liver,  the  portal  vein  embolization  had
een  performed  anyway.  The  portal  vein  embolization  was
etermined  for  these  three  patients  because  the  tumor  was
 hilar  cholangiocarcinoma,  with  dilatation  of  intrahepatic
d
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ile  ducts  that  can  lead  to  a  poorer  liver  regeneration  after
nprepared  surgery.
We  did  not  take  into  account  the  complexity  of  the
esection  in  calculating  the  necessary  percentage  of  func-
ional  liver  volume.
Exclusion  criteria  were  as  follows:  unresectable  tumor
arterial  invasion,  bilobar  disease,  stage  IV  hilar  cholan-
iocarcinoma),  metastatic  disease  (extra-hepatic  or  lym-
hadenopathy),  portal  vein  occlusion  and/or  renal  failure.
Endoscopic  (n  =  2)  or  percutaneous  (n  =  7)  biliary  drainage
as  performed  in  patients  with  biliary  obstruction  at  least
 week  before  PVE,  associated  with  short  intravenous  antibi-
tic  therapy  (ceftriaxone  and  metronidazole  antibiotics)
mmediately  before  the  procedure  and  during  the  next
 days.
ortal vein embolization
mbolization  was  performed  under  general  anesthesia  by
ne  of  the  three  vascular  and  interventional  radiology
aculty  members.  For  the  percutaneous  approach  in  our
nstitution,  we  use  a  platelet  count  greater  than  50,000/mL
nd  Prothrombin  Time  greater  than  50%,  as  recommended  in
he  literature  [1].  Otherwise,  patients  were  transfused  with
ppropriate  factors.
The  portal  venous  system  was  accessed  percutaneously
nder  sonographic  and  ﬂuoroscopic  guidance  using  a  con-
ralateral  approach.
A  22-gauge  Chiba  needle  (Neff  Percutaneous  Access  Set®;
ook,  Bloomington,  Indiana,  USA)  was  introduced  into  a  dis-
al  portal  vein  and  then,  thanks  a  5-F  vascular  sheath  used
o  facilitate  subsequent  catheter  exchanges.
Flush  portography  was  performed  with  a  5-F  catheter
Cook,  Europe;  Bjaeverskov,  Denmark)  or  a  5-F  cobra-shaped
atheter  (Cobra®;  Terumo,  Tokyo,  Japan)  in  the  main  portal
ein  (Fig.  1).  Anteroposterior,  right  and  left  anterior  oblique
rojections,  were  obtained  as  needed  to  delineate  the  por-
al  vein  anatomy.
Selective  right  anterior  and  posterior  portal  vein
njections  were  performed.  In  each  branch,  trisacryl  micro-
pheres  (Embosphere®; Biosphere  Medical,  Roissy,  France)
anging  from  300  to  1200  microns  were  administered  in
 stepwise  fashion:  smaller  particles  were  used  ﬁrst  to
cclude  the  distal  branches,  and  larger  particles  were  used
ubsequently  to  occlude  the  more  proximal  branches.  The
arger  particles  were  not  used  until  the  forward  portal  blood
ow  was  substantially  reduced.  Additional  embolization
ith  gelatin  sponge  particles  (Gelitaspon®; Gelita  Medi-
al  BV,  Amsterdam,  the  Netherlands)  was  performed  until
ear-complete  stasis  was  achieved.  Then,  0.035-inch  coils
Tornado® or  Nester® or  both,  Cook  Medical,  Bloomington,
ndiana,  USA)  were  placed  within  the  proximal  right  ante-
ior  and  posterior  portal  veins  branches  or  the  right  portal
ein  (if  long  enough)  to  further  reduce  the  portal  inﬂow
hat  could  lead  to  recanalization.  If  a  right  hepatectomy
xtended  to  the  segment  IV  was  planned,  the  same  proce-
ure  was  performed  to  occlude  segment  IV  of  the  liver.
A  ﬁnal  portogram  was  obtained  with  the  ﬂush  catheter
ositioned  in  the  main  portal  vein  to  assess  the  completeness
f  the  embolization  (Fig.  2).
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fFigure 1. Initial portography in a patient with hepatocellular ca
image. White arrow: 5-F catheter in the main portal vein; MPV: ma
At  the  end  of  the  procedure,  the  catheter  was  removed
under  manual  compression  during  5  minutes,  without  any
tract  embolization.
No  patient  had  clinical  or  radiological  evidence  of  pre-
existing  portal  hypertension;  therefore,  portal  vein  pressure
was  not  measured.
Clinical evaluation
PVE  was  performed  during  a  short  hospitalization  in  the
surgery  department.  No  medication  was  systematically
administered  after  the  procedure.  Clinical  and  biological
evaluation  depicted  post-embolization  syndrome,  liver  fail-
ure  or  catheter  related  complications.  All  patients  were
p
1
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Figure 2. Final portography, showing coils in the different branches o
right liver lobe but a patency of the branches of the left portal vein. Whima in the right liver lobe: a: native image; b: digital substraction
rtal vein; RPV: right portal vein.
npatients  and  stayed  in  the  hospital  for  at  least  one  night.
atients  were  discharged  when  they  were  found  to  be  in
 clinically  stable  condition  by  surgical  and  interventional
adiology  staff.
The  outcomes  were  assessed  by  recording  all
omplications  according  to  the  Society  of  Interventional
adiology  Standards  of  Practice  Committee  Classiﬁcation  of
omplications  by  Outcome  [4]  after  PVE  during  the  hospi-
alization  and  at  the  preoperative  consultation  within  the
ew  days  after  the  post-embolization  CT.  Post-embolization
ain  was  graded  with  a  numerical  scale  ranging  from  1  to
0.
Technical  success  rate  was  deﬁned  as  the  successful
cclusion  of  the  branch  of  the  right  portal  vein  after  PVE.
f the right portal vein (dashed arrows), no vascularization of the
te arrow: 5-F catheter in the main portal vein for the ﬁnal control.
60  
Figure 3. Axial portal venous phase CT in a 65-year-old man, with
hepatocellular carcinoma developed on alcoholic cirrhosis obtained
22 days before the portal vein embolization. IV, I and LLL correspond
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io segment IV, I and the left liver lobe respectively, GB corresponds
o the gallbladder.
Clinical  success  was  deﬁned  as  the  operability  rate,
ost-PVE  and  post-surgery  complications  and  hepatic  insuf-
ciency.
ssessment of  hypertrophy
 CT-scan  of  the  abdomen  and  pelvis  was  repeated  before
nd  approximately  3  weeks  after  PVE  to  evaluate  tumor  pro-
ression  and  to  perform  volumetric  measurements.
The  CT-scan  protocol  used  to  deﬁne  precisely  the  liver
egments  was  a  triple  phase  CT  (one  acquisition  without
ontrast  media  injection,  and  two  contrasts  enhanced  acqui-
itions  at  arterial  phase,  obtained  35  seconds  after  injection
nd  portal  venous  phase  obtained  90  seconds  after  injec-
ion).  All  measurements  were  obtained  on  the  portal  venous
hase,  to  delineate  more  precisely  the  hepatic  veins.
Volumetric  measurements  were  performed  by  a  single
adiologist,  using  the  semi-automatic  ADW  4.5  GE  software
n  3  mm-thick  slices.  These  measurements  included:  total
iver  volume,  tumor  volume,  segment  IV  volume,  segment
 volume,  and  segments  II  and  III  volume.  Total  functional
iver  volume  (TLV)  was  deﬁned  as  the  total  liver  volume
F
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P
igure 4. Axial portal venous phase CT obtained 23 days after portal
he left liver lobe and the gallbladder respectively. Image (a) is obtained
nfarcts in the sub capsular part of the right liver lobe. Black arrow (b) cJ.  Cazejust  et  al.
inus  the  tumor  volume.  In  addition,  FLR  volume  was
alculated.  Depending  on  the  patient  and  tumor  exten-
ion,  the  volume  of  the  FLR  was  calculated  as  the  sum
f  segments  II  and  III  volumes  ±  segments  I and/or  IV
olumes.  Finally,  the  ratio  between  the  FLR  and  the  TLV  was
alculated.  Hypertrophy  rates  were  calculated  as  follow:
FLR  post-embolization—FLR  pre-embolization)/(Total  liver
olume—Tumor  volume),  as  previously  described  in  the
iterature  [5].
The  selection  of  patients  for  surgical  treatment  was
ased  on  the  evaluation  of  disease  extent,  volumetric  CT
nalysis  [6],  and  the  FLR  measurements  performed  immedi-
tely  before  surgery  (Figs.  3  and  4).
Tumor  progression  was  deﬁned  as  the  detection  of  extra-
epatic  metastasis,  left  hepatic  tumor  or  an  increase  of
reexisting  tumor  that  contraindicate  surgery  (vascular
nvasion).
To  assess  the  efﬁcacy  of  PVE,  FLR  volumes  were  compared
efore  and  after  embolization.  The  mean  absolute  FLR  vol-
mes  (in  cm3) and  FLR/TLV  ratios  were  calculated  before  and
fter  embolization  to  determine  the  degree  of  hypertrophy.
tatistical analysis
ll  data  were  expressed  as  means  ±  standard  deviations
SD).  The  Mann—Whitney  test  and  the  Fisher  exact  test
ere  used  to  compare  continuous  and  categorical  variables,
espectively.  The  rates  of  hepatic  resection  were  analyzed,
nd  the  Fisher  exact  test  was  used  to  determine  if  the
ifferences  were  statistically  signiﬁcant  (P  <  0.05).  Spear-
an’s  rank  coefﬁcient  was  used  to  calculate  the  correlation
etween  two  continuous  variables.  The  Wilcoxon  signed-
ank  test  was  used  for  matched  comparisons.  Statistical
igniﬁcance  was  set  at  a  P-value  <  0.05.  All  analyses  were
erformed  with  SAS  v.9.2  (Sas  Institute  Inc.,  Cary,  North
arolina,  USA).
esults
tudy populationrom  February  2009  to  January  2013,  31  patients  (52  men
nd  11  women)  were  considered  for  right  hepatectomy  after
VE  for  hepatobiliary  malignancy.
 vein embolization. IV, I, LLL and GB correspond to segment IV, I,
 at the same plane as Fig. 3. White arrows (a) correspond to distal
orresponds to post-portal vein embolization coils.
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Table  1  Patients  demographics.
Sex  (M/F)  52/11
Age  (years,  mean,  range)  63  [38—80]
Tumor  type  (n/%)
HCC  (38/60)
Cholangiocarcinoma  (11/18)
Metastasis  (14/22)
Vials  of  microparticles  (mean,  SD)  8.9  ±  1.8
Coils  (mean,  SD)  14.1  ±  4.2
Resection  rate  (n/%)  49/78%
Resection  rate  according  to  tumor  type
HCC  (30/38)
Cholangiocarcinoma  (4/11)
Metastasis  (2/14)
M: men; F: female; n: number; SD: standard deviation.
Table  2  Volumetric  measurements  before  and  after
portal  vein  embolization.
Before  PVE  After  PVE
TLV  (cm3: mean,  SD)  1.825  ±  91  1.934  ±  83
FLR  (cm3:  mean,  SD)  449  ±  180  663  ±  254
FLR/TLV  (%)  25  ±  8  36  ±  12
Hypertrophy  of  FLR  (%)  57  ±  56
Increase  of  the  FLR/TLV  ratio  (%)  11  ±  7
TLV: total liver volume; FLR: future liver remnant; SD: standard
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iThe  mean  age  was  63  years  old  (ranging  from  38  to  80
years).  All  patients  had  advanced  hepatobiliary  malignancies
(hepatocellular  carcinoma  in  38  patients,  cholangiocarci-
noma  in  11  patients  and  liver  metastasis  from  colorectal
cancer  in  14  patients)  and  required  right  hepatectomy.
The  diagnosis  of  malignancy  was  either  a  biopsy-proven
malignant  neoplasia  (n  =  29)  or  typical  imaging  ﬁndings
on  multi-detector  CT  and/or  magnetic  resonance  imag-
ing  (n  =  34).  The  demographical  and  histological  parameters
were  reported  in  Table  1.
Among  the  38  patients  with  hepatocellular  carcinoma,  37
had  liver  cirrhosis  (all  patients  were  classiﬁed  as  Child—Pugh
class  A).  The  cause  of  cirrhosis  was  viral  hepatitis  B  (n  =  9),
viral  hepatitis  C  (n  =  11),  alcoholism  (n  =  8),  viral  hepati-
tis  C  and  alcoholism  (n  =  5),  non-alcoholic  steatohepatitis
(n  =  3),  or  hemochromatosis  (n  =  1).  The  three  patients
with  liver  metastases  received  prior  chemotherapy  (Fol-
fox).
Concerning  the  embolic  agents  (Table  1),  we  used
a  mean  number  of  8.9  ±  1.8  vials  of  particles  ranging
from  300  to  1200  m  which  correspond  to  a  volume  of
15.3  ±  3.1  mL  of  particles;  and,  at  most,  one  entire  gelfoam
pad  cut  per  patient.  A  mean  of  14.1  ±  4.2  coils  were  used
to  obtain  the  right  portal  vein  branches  occlusion.  The
amount  of  contrast  media  used  for  the  procedure  was
467  ±  113  mL.
Clinical evaluation
Puncture  of  the  distal  part  of  the  segment  III  portal  branch
was  performed  in  all  cases,  and  technical  success  rate  of
PVE  was  100%,  achieving  a  complete  occlusion  of  all  right
portal  vein  branches.
No  patient  developed  post-embolization  syndrome,  grade
3  or  4  pain  after  PVE  or  progressive  liver  failure  after
PVE  or  surgery.  No  patient  required  a  speciﬁc  medication
after  embolization.  No  subcapsular  hematoma  or  thrombo-
sis  was  found  at  the  site  of  the  left  branch  puncture  of
the  left  portal  branch  on  the  post-embolization  volumetric
CT-scan.
The  median  length  of  hospital  stay  was  2  days  (ranging
from  1  to  4  days)  for  PVE.
R
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sdeviation; PVE: portal vein embolization.
omplications of PVE
even  complications  occurred  as  a  result  of  PVE,  though
one  was  directly  related  to  the  particular  embolic  agent
sed.  Three  patients  developed  minors  complications  and
our  portal  hypertension  that  contraindicate  surgery.
Four  patients  developed  signs  of  portal  hypertension  on
ollow-up  CT  imaging,  and  two  of  them  had  measurements
f  portal  pressure  via  transjugular  approach  to  conﬁrm  CT-
can  ﬁndings.  These  patients  were  not  operated  on  because
f  the  portal  hypertension.
One  patient  developed  an  intrahepatic  portovenous  shunt
n  the  side  of  portal  venous  puncture,  between  the  distal
art  of  the  left  hepatic  vein  and  the  distal  part  of  the  seg-
ent  III  portal  branch.  This  shunt  was  stable  according  to  the
oppler  and  multi-detector  CT  performed  during  follow-up
xamination,  even  after  right  hepatectomy.
Two  patients  had  one  coil  displacement,  in  the  left  portal
ein.  The  coils  were  then  removed  with  a  10-mm  Amplatz
ooseNeck® Snare  Kit  (EV3,  White  Bear  Lake,  Minnesota,
SA).  Intra-portal  IV  anticoagulant  therapy  was  injected.
he  left  portal  branch  patency  was  conﬁrmed  by  ﬁnal  por-
ography,  US-Doppler  examination  of  24  hours  and  on  pre-
nd  post-hepatectomy  CT-scans.
ssessment of hypertrophy
ll  post-embolization  volumetric  CT-scans  were  performed
rom  14  to  35  days  (mean  of  24  days  ±  6  days)  after  PVE.  The
ean  TLVs  were  1.825  ±  91  cm3 before  and  1.934  ±  83  cm3
fter  PVE.  The  mean  absolute  FLR  volumes  were  449  ±  180
efore  and  663  ±  254  cm3 after  PVE.  The  mean  absolute  FLR
olume  increased  by  57%  ±  56%  (P  <  0.0001).  Volumetric  data
re  reported  in  Table  2.
The  pre-embolization  FLR/TLV  ratio  was  25%  ±  8%,  and
he  post-embolization  FLR/TLV  ratio  was  36%  ±  12%.  The
ean  increase  in  the  FLR/TLV  ratio  after  PVE  was  11%  ±  7%
P  <  0.0001).
There  was  no  signiﬁcant  difference  in  FLR  hypertro-
hy  according  to  age  (P  =  0.53),  sex  (P  =  0.28),  tumor  type
P  =  0.32)  or  liver  cirrhosis  (P  =  0.13).
The  degree  of  hypertrophy  negatively  correlated  with  the
nitial  FLR  volume  (r  =  −0.37;  P  =  0.024).esection rate and outcome
f  the  63  patients  who  underwent  PVE,  49  (78%)  underwent
uccessful  right  hepatectomy  four  to  7  weeks  after  PVE.  No
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eath  was  recorded  up  to  2  months  after  surgery,  and  no
ase  of  postoperative  liver  failure  was  recorded.
Fourteen  patients  (22%)  did  not  undergo  resection
ecause  of  tumor  progression  (n  =  9),  inadequate  hypertro-
hy  (n  =  1)  or  portal  hypertension  (n  =  4).
For  13  patients,  although  the  percentage  of  theoretical
LR  needed  was  not  obtained,  the  right  hepatectomy  was
erformed  anyway.
Eight  of  them  (with  a  healthy  liver)  had  a  future  liver
emnant  of  20  to  23%  (theoretical  value  recommended  is
5%  or  more).  Six  of  them  (with  a  cirrhotic  liver)  had  a  future
iver  remnant  of  35  to  39%  (theoretical  value  recommended
s  40%  or  more).
iscussion
espite  the  decrease  in  postoperative  complications  after
iver  resection  over  the  past  10  years,  insufﬁcient  hepatic
unctional  reserve,  suggested  by  a  small  FLR  volume  after
ajor  liver  resection,  is  still  considered  a  risky  situation.
Major  hepatectomy  (i.e.,  resection  of  four  or  more  liver
egments)  is  associated  with  increased  morbidity  and  mor-
ality.  The  increase  in  mortality  has  been  reported  as  high
s  0.5  to  4%  in  patients  with  a  healthy  liver  [7]  and  from  4
o  12%  in  patients  with  a  cirrhotic  liver  [8,9].  Postoperative
omplications  are  mainly  due  to  liver  failure.
Therefore,  by  hypertrophying  the  FLR,  the  safety  and
olerance  of  major  liver  resections  might  be  improved.
ased  on  this  hypothesis,  PVE  has  been  proposed  to  increase
he  size  of  the  FLR  after  major  hepatectomy,  thus  reducing
he  risk  of  postoperative  liver  insufﬁciency.  PVE  consists  of
reoperatively  embolizing  portal  branches  of  the  segments
hat  will  be  resected.  PVE  has  been  used  in  patients  with
r  without  chronic  liver  disease,  and  with  diseases  such
s  cholangiocarcinoma,  hepatocellular  carcinoma  and  liver
etastases  [8].
PVE  is  a  well-established  procedure,  but  it  is  extremely
ariable  from  one  center  to  another,  probably  because  there
s  no  ofﬁcial  recommendation  for  using  a  speciﬁc  embolic
gent  [1].  No  monocentric,  comparative  study  has  exam-
ned  which  embolic  agent  would  provide  better  hypertrophy,
ut  according  to  the  recent  literature,  n-butyl  cyanoacry-
ate  (NCBA)  and  trisacryl  microspheres  appear  to  be  the
wo  most  commonly  used  embolic  agents  [10].  However,
elfoam  [11],  coils  [12],  alcohol  [13],  and  nitinol  plugs
14,15]  alone  or  in  combination  [16—20]  have  also  been
sed  as  embolic  agents,  but  seem  less  efﬁcient  because
f  recanalization  of  the  portal  vein  and/or  low  hypertro-
hy  of  the  FLR.  Moreover,  the  rate  of  hypertrophy  after  PVE
epends  on  the  pre-embolization  FLR  volume  more  than  any
ther  factor,  as  described  previously  [12].  Since  1990  PVE
as  proposed  as  a  mean  to  prepare  the  patient  and  liver
or  extended  resection  [21],  reﬁned  indications,  techniques
nd  embolization  materials  have  contributed  to  improve  the
utcomes  of  the  procedure  and  the  subsequent  extended
epatic  resection.
To  summarize  our  results,  we  performed  successfully  31
eft  percutaneous  transhepatic  PVE  approach,  with  the  use
f  a  mean  number  of  8.9  ±  1.8  vials  of  particles,  plus  par-
icles  of  gelfoam  pad  cut  and  a  mean  of  14.1  ±  4.2  coils.
o  patient  developed  post-embolization  syndrome  and  the
p
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ean  hospital  stay  was  2  days.  Four  complications  (3  minor
nd  one  portal  hypertension)  occurred  as  a result  of  PVE.  The
ean  absolute  FLR  volume  increased  by  57%  ±  56%  and  the
ean  increase  in  the  FLR/TLV  ratio  after  PVE  was  11%  ±  7%.
f  the  63  patients  who  underwent  PVE,  49  underwent  suc-
essful  right  hepatectomy,  without  death  up  to  2  months
fter  surgery,  and  no  case  of  postoperative  liver  failure.  Fif-
een  patients  had  a  limited  hypertrophy  of  FLR,  but  only  one
ad  not  been  operated  on.
There  is  no  clear  rationale  for  the  use  of  three  embolic
gents.  However,  this  could  be  a  more  reproducible
rocedure,  since  we  use  systematically  at  least  a  vial
f  each  particle  size  (300—500;  500—700;  700—900  and
00—1200  m)  in  the  different  embolized  portal  branches.
oreover,  at  the  end  of  procedure,  slowing  the  ﬂow  in
he  right  portal  branch  may  cause  a  reﬂux  of  embolization
aterial  in  the  future  liver  remnant.  The  use  of  gelfoam  at
he  end  of  procedure  could  minimize  this  risk,  since  gelfoam
s  an  absorbable  agent.  Finally,  although  we  did  not  conduct
 study  of  cost,  the  use  of  Gelfoam  has  allowed  us  to  use
ess  trisacryl  microspheres,  which  are  more  expensive  than
elfoam.
Our  PVE  procedure  consisted  in  all  cases  of  a transhepatic
ontralateral  approach,  whereas  ipsilateral  or  contralateral
pproaches  were  described  in  the  literature.  We  used  this
echnique  because  it  seemed  easier  for  us  to  catheterize
he  anterior  and  posterior  right  portal  branches.  Moreover,
he  contralateral  approach  allows  us  to  better  control  the
elease  of  coils  starting  distally  in  the  right  portal  vessels,
o  perform  a ﬁnal  portography  and  to  use  it  as  a good  tool  to
easure  intra-portal  pressure  before  and  after  portal  vein
mbolization  if  needed.
PVE  is  indicated  based  on  preoperative  CT  measurements
6]  of  the  FLR  and  its  ratio  with  either  the  theoretical  TLV
r  by  a  direct  measurement  of  the  functional  liver  vol-
me.  According  to  the  literature,  the  FLR/TLV  ratio  should
e  at  least  equal  to  25%  in  a healthy  liver,  equal  to  30%
fter  chemotherapy  and  equal  to  40%  in  a cirrhotic  liver
19,22—27].
Three-dimensional  volumetric  CT-scan  is  the  method  of
hoice  for  assessing  TLV  and  FLR  [28—30]. The  average  time
eriod  between  PVE  and  post-embolization  volumetric  CT-
can  should  be  approximately  3  to  4  weeks  [31], as  in  our
tudy  (mean  of  26  days,  ranging  from  16  to  32  days).
Our  results  suggest  that  hypertrophy  after  PVE  is
nversely  correlated  with  the  initial  FLR  volume,  even  in  a
irrhotic  liver  (r  =  −0.37;  P  =  0.024).  These  results  conﬁrm
hose  of  a  recent  study  by  de  Baere  et  al.  [12]  on  PVE  in
atients  with  malignant  disease  and  a  non-cirrhotic  liver.
Our  PVE  procedure  consisted  of  a  transhepatic  con-
ralateral  approach  and  the  use  of  a combination  of  three
mbolization  agents,  which  are  already  used  separately,
ut  not  in  combination,  to  the  best  of  our  knowledge.
lthough  this  study  is  not  a  randomized  trial  focused  on
omparing  different  agents  of  embolization,  the  hypertro-
hy  resulting  from  the  PVE  technique  used  was  comparable
o  that  found  in  series  reported  in  the  literature  using
ther  techniques.  Moreover,  no  case  of  liver  failure,  severe
ain  or  post-embolization  syndrome  was  observed  with  this
echnique,  which  indicates  that  it  did  not  result  in  a  higher
ate  of  complications  than  other  techniques  described  in  the
iterature.
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There  are  several  limitations  to  our  study  in  addition
to  the  small  number  of  patients  and  its  retrospective
design.  The  diseases  studied  were  varied:  hepatocellular
carcinoma  (in  all  but  one  developed  on  liver  cirrhosis),
cholangiocarcinoma  (the  liver  was  most  often  healthy)  and
liver  metastases  in  patients  who  have  had  chemotherapy
(which  can  affect  the  liver  and  its  potential  ability  to
regenerate).  Moreover,  in  case  of  liver  cirrhosis,  the  causes
of  cirrhosis  were  heterogeneous.
For  fourteen  patients,  although  the  percentage  of
theoretical  FLR  needed  was  not  obtained,  the  right  hep-
atectomy  was  performed  anyway.  Surgeons  argued  that
surgery  was  the  only  curative  treatment  available  for  these
patients.  Four  of  them  (with  a  healthy  liver)  had  a  future
liver  remnant  of  20  to  23%  (theoretical  value  recommended
is  25%  or  more).  Three  of  them  (with  a  cirrhotic  liver)
had  a  future  liver  remnant  of  35  to  39%  (theoretical  value
recommended  is  40%  or  more).
Although  the  combined  use  of  microparticles  and  gelfoam
could  allow  us  to  use  less  of  microparticles  (higher  cost),  we
have  not  been  able  to  make  cost  study,  which  would  probably
be  important  to  make  in  these  economical  difﬁcult  periods.
Our  study  shows  similar  results  to  those  in  the  litera-
ture  obtained  with  other  agents  of  embolization  in  terms
of  hypertrophy  of  the  future  liver  remnant,  but  it  is  not
a  comparative  study.  These  results  are  to  be  compared  to
the  Madoff  at  al.  ones  [23],  using  spherical  particles  (from
100  to  700  m)  and  coils,  with  a  mean  FLR  increase  of  69%
and  mean  FLR/TELV  of  9.7%.  In  this  study  about  44  patients,
three  patients  had  an  inadequate  hypertrophy  and  the  over-
all  resection  rate  was  71%.  In  a  recent  systematic  review
of  PVE  before  liver  resection  including  44  articles  [2]  the
hypertrophy  rate  of  the  FLR  was  24  to  26%  with  the  use  of
PVA  +  coils  while  the  mean  increase  of  the  FRL  volume  was
37.9  ±  0.1%  (20.5—69.4%).
A  recent  retrospective  study  [3]  comparing  the  results  of
PVE  using  two  PVE  procedures  showed  that  the  use  of  NBCA
(20  patients)  seems  more  effective  than  the  use  of  spherical
100—300  m  microparticles  and  coils  (14  patients).  These
results  are  to  be  compared  to  an  experimental  study  in  a
pig  model,  which  have  demonstrated  an  advantage  of  NCBA
over  three  other  embolic  agents  [16].
It  would  be  interesting  to  conduct  a  prospective,
randomized  study  to  compare  the  rates  of  hypertrophy
using  several  methods  of  embolization,  the  length  of  this
procedure  and  the  cost.
Conclusion
In  conclusion,  our  results  suggest  that  PVE  using  the
combination  of  three  different  embolic  agents  (trisacryl
microspheres,  gelfoam  and  coils)  is  a  safe,  well-tolerated
and  effective  method  for  inducing  contralateral  hypertro-
phy  before  right  hepatectomy  in  patients  with  advanced
hepatobiliary  malignancies.Disclosure of interest
The  authors  declare  that  they  have  no  conﬂicts  of  interest
concerning  this  article.63
eferences
[1] Denys A, Bize P, Demartines N, Deschamps F, De Baere T. Quality
improvement for portal vein embolization. Cardiovasc Inter-
vent Radiol 2010;33:452—6.
[2] Van Lienden KP, van den Esschert JW,  de Graaf W, Bipat S,
Lameris JS, van Gulik TM, et al. Portal vein embolization
before liver resection: a systematic review. Cardiovasc Inter-
vent Radiol 2013;36:25—34.
[3] Guiu B, Bize P, Gunthern D, Demartines N, Halkic N, Denys A.
Portal vein embolizaion before right hepatectomy: improved
results using n-butyl cyanoacrylate compared to microparticles
plus coils. Cardiovasc Intervent Radiol 2013 [Epub ahead of
print] http://www.ncbi.nlm.nih.gov/pubmed/23361117
[4] Omary RA, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg
MS, Sacks D, et al. Quality improvement guidelines for the
reporting and archiving of interventional radiology procedures.
J Vasc Interv Radiol 2002;13:879—81.
[5] de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V.
Preoperative portal vein embolization for extension of hepate-
ctomy indications. Hepatology 1996;24:1386—91.
[6] Soyer P, Roche A, Elias D, Levesque M. Hepatic metas-
tases from colorectal cancer: inﬂuence of hepatic volumetric
analysis on surgical decision-making. Radiology 1992;184:
695—7.
[7] Nordlinger B, Peschaud F, Malafosse R. Resection of liver metas-
tases from colorectal cancer–how can we improve results?
Colorectal Dis 2003;5:515—7.
[8] Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro
R, Vilgrain V, et al. Portal vein embolization before right
hepatectomy: prospective clinical trial. Ann Surg 2003;237:
208—17.
[9] Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clin-
ical score for predicting recurrence after hepatic resection
for metastatic colorectal cancer: analysis of 1001 consecutive
cases. Ann Surg 1999;230:309—18 [discussion p. 318—321].
10] Denys A, Prior J, Bize P, Duran R, De Baere T, Halkic N, et al. Por-
tal vein embolization: what do we know? Cardiovasc Intervent
Radiol 2012;35:999—1008.
11] de Baere T, Roche A, Vavasseur D, Therasse E, Indushekar
S, Elias D, et al. Portal vein embolization: utility for induc-
ing left hepatic lobe hypertrophy before surgery. Radiology
1993;188:73—7.
12] de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P,
Hakime A, et al. Predictive factors for hypertrophy of the
future remnant liver after selective portal vein embolization.
Ann Surg Oncol 2010;17:2081—9.
13] Ogasawara K, Uchino J, Une Y, Fujioka Y. Selective por-
tal vein embolization with absolute ethanol induces hepatic
hypertrophy and makes more extensive hepatectomy possible.
Hepatology 1996;23:338—45.
14] Bent CL, Low D, Matson MB, Renfrew I, Fotheringham T. Portal
vein embolization using a nitinol plug (Amplatzer vascular plug)
in combination with histoacryl glue and iodinized oil: adequate
hypertrophy with a reduced risk of nontarget embolization.
Cardiovasc Intervent Radiol 2009;32:471—7.
15] Kalenderian AC, Chabrot P, Buc E, Cassagnes L, Ravel A,
Pezet D, et al. Preoperative portal vein embolization with
Amplatzer(®) vascular plugs (AVP): a review of 17 cases. J
Radiol 2011;92:899—908.
16] de Baere T, Denys A, Paradis V. Comparison of four embolic
materials for portal vein embolization: experimental study in
pigs. Eur Radiol 2009;19:1435—42.
17] Denys A, Lacombe C, Schneider F, Madoff DC, Doenz F, Qanadli
SD, et al. Portal vein embolization with N-butyl cyanoacrylate
before partial hepatectomy in patients with hepatocellular car-
cinoma and underlying cirrhosis or advanced ﬁbrosis. J Vasc
Interv Radiol 2005;16:1667—74.
6[
[
[
[
[
[
[
[
[
[
[
[
[
512—9.4  
18] Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization
in preparation for major hepatic resection: evolution of a new
standard of care. J Vasc Interv Radiol 2005;16:779—90.
19] Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal
vein embolization with polyvinyl alcohol particles and coils in
preparation for major liver resection for hepatobiliary malig-
nancy: safety and effectiveness: study in 26 patients. Radiology
2003;227:251—60.
20] Madoff DC, Hicks ME, Vauthey JN, Charnsangavej C, Morello
Jr FA, Ahrar K, et al. Transhepatic portal vein embolization:
anatomy, indications, and technical considerations. Radio-
graphics 2002;22:1063—76.
21] Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén
P, et al. Preoperative portal embolization to increase safety of
major hepatectomy for hilar bile duct carcinoma: a preliminary
report. Surgery 1990;107:521—7.
22] Ferrero A, Viganò L, Polastri R, Muratore A, Eminefendic H,
Regge D, et al. Postoperative liver dysfunction and future rem-
nant liver: where is the limit? Results of a prospective study.
World J Surg 2007;31:1643—51.
23] Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A,
et al. Transhepatic ipsilateral right portal vein embolization
extended to segment IV: improving hypertrophy and resection
outcomes with spherical particles and coils. J Vasc Interv Radiol
2005;16:215—25.
24] Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM,
Lemoine A, et al. Percutaneous portal vein embolization
increases the feasibility and safety of major liver resection
for hepatocellular carcinoma in injured liver. Ann Surg
2000;232:665—72.
[J.  Cazejust  et  al.
25] Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa
K, et al. Measurement of liver volume and hepatic functional
reserve as a guide to decision-making in resectional surgery for
hepatic tumors. Hepatology 1997;26:1176—81.
26] Capussotti L, Muratore A, Baracchi F, Lelong B, Ferrero A, Regge
D, et al. Portal vein ligation as an efﬁcient method of increasing
the future liver remnant volume in the surgical treatment of
colorectal metastases. Arch Surg 2008;143:978—82.
27] Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P,
Jackson J, et al. Preoperative portal vein embolization for
major liver resection: a meta-analysis. Ann Surg 2008;247:
49—57.
28] Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K,
Utsunomiya T, et al. Postoperative liver failure after major
hepatic resection for hepatocellular carcinoma in the modern
era with special reference to remnant liver volume. J Am Coll
Surg 1999;188:304—9.
29] Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami
T, Ishizone S, et al. Calculation of child and adult
standard liver volume for liver transplantation. Hepatology
1995;21:1317—21.
30] Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher
MJ, Charnsangavej C, et al. Standardized measurement of
the future liver remnant prior to extended liver resection:
methodology and clinical associations. Surgery 2000;127:31] Ribero D, Chun YS, Vauthey JN. Standardized liver volume-
try for portal vein embolization. Semin Intervent Radiol
2008;25:104—9.
